CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 5–8, 2009 in New Orleans, Louisiana. These abstracts include an oral presentation of data on successful VELCADE utilization in both induction and maintenance in the front-line setting during the distinguished plenary session being held on Sunday, December 6. The ASH Program Committee selects for the plenary session the most ground-breaking abstracts of the conference. Other key abstracts to be highlighted during the meeting include data on VELCADE as a foundation of therapy for a broad spectrum of patients with multiple myeloma (MM); an update on the survival benefit of VELCADE in the front line setting; the cost-effectiveness of VELCADE treatment for patients with MM; and VELCADE in patients with non-Hodgkin’s lymphoma (NHL).
